This obesity-associated hyperleptinaemia is not merely a metabolic byproduct but also strengthens the connection between leptin and breast cancer advancement: obese breast cancer patients exhibit higher leptin levels than non-obese counterparts, and this elevation correlates with larger tumour size, increased lymph node metastasis, and poorer prognosis [27,28]. This evidence concerns the gene LEP and breast carcinoma.